Medtronic (NYSE:MDT) posted a mixed set of Q3 FY’22 results. While revenues missed expectations, remaining roughly flat year-over-year at $7.8 billion, adjusted EPS was in-line with estimates at $1.37. Guidance for Q4 was also in-line with estimates.
The sales of some devices, such as its pelvic health products were impacted as the surge in omicron virus cases resulted in deferred procedures in Q3. However, the company says that it is seeing improving volumes with demand for its heart devices remaining strong.
Medtronic stock gained almost 3% in Tuesday’s trading.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
|S&P 500 Return||-5%||-10%||92%|
|Trefis MS Portfolio Return||-3%||-12%||246%|
 Month-to-date and year-to-date as of 2/23/2022
 Cumulative total returns since the end of 2016